To identify appropriate NPC epigenetic biomarkers for clinical use, a group of scientists at the University of Hong Kong performed methylation-sensitive resolution melting (MS-HRM) assays to quantitate the methylation states of four hypothetical tumor suppressors, i.e., RASSF1, WIF1, DAPK1, and RARB, in 220 and 50 plasma samples from NPC patients and control individuals, respectively. This evidence concerns the gene DAPK1 and nasopharyngeal carcinoma.